Press Releases I-Mab

Equities

IMAB

US44975P1030

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-1.13%		-3.31%	-7.89%

Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT
Apr. 15	I-Mab Announces Chief Medical Officer Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-MAB Filed 2023 Annual Report on Form 20-F	Apr. 30	PR
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 08	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 05	PR
I-Mab Announces Closing of the Divestiture of Business Operations in China	Apr. 02	PR
I Mab : Resignations of Director and Senior Management - Form 6-K	Apr. 01	PU
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	Feb. 08	AQ
I-Mab Announces Participation at Jefferies and Piper Conferences in November	Nov. 06	PR
I-Mab - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy	Nov. 03	AQ
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	Nov. 01	PR
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	23-10-16	PR
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503	23-10-11	AQ
I Mab : Regains Global Rights to Lemzoparlimab - Form 6-K	23-09-21	PU
I-Mab Announces Upcoming Participation at September Conferences	23-09-05	PR
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates	23-08-18	AQ
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023	23-08-08	PR
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma	23-07-11	AQ
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC	23-07-05	PR
I-Mab Announces the Appointment of Raj Kannan as CEO	23-06-22	PR
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma	23-06-15	AQ
I-MAB Filed 2022 Annual Report on Form 20-F	23-05-01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases I-Mab

Equities

IMAB

US44975P1030

Press Releases

Filters